Target
CD20+
119 abstracts
Abstract
Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status.Org: Dana-Farber Cancer Institute, Institut Català D'Oncologia, Leiden University Medical Center, Rigshospitalet, Copenhagen University Hospital, Ronald Reagan University of California Los Angeles Medical Center,
Abstract
Very long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study.Org: Institut Curie, Saint Cloud, France, Hemato-oncology, IUCT-Oncopole Toulouse, Department of Hemagology, Centre François Magendie,
Abstract
Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study.Org: F. Hoffmann-La Roche Ltd, Roche Products Ltd., City of Hope National Medical Center, Humanitas University and IRCCS Humanitas Research Hospital, Centre Hospitalier Universitaire de Lille,
Abstract
Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.Org: St. Vincent’s Hospital, The Catholic University of Korea, Haematology Unit, Royal Adelaide Hospital, Sungkyunkwan University School of Medicine,
Abstract
Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.Org: Mayo Clinic, Memorial Sloan Kettering Cancer Center, Cleveland Clinic Lerner College of Medicine, The Ohio State University - Division of Hematology, Washington University School of Medicine,
Abstract
Effect of placental circulating T cells expressing CD16 on multiple hematological and solid tumor cancers through combination with various monoclonal antibodies.Org: Celularity Inc.,
Abstract
Development of NTX-472, a formulated mRNA therapy targeting CD20, CD19, and CD47, for treatment of B-cell lymphoma.Org: Nutcracker Therapeutics, Emeryville, CA,
Abstract
The anti-CD20 antibody-drug conjugates TRS005 in relapse/refractory CD20-positive B-cell non-Hodgkin lymphoma: A multicenter, open-label, single-arm, phase I study.Org: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Cancer Center/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Henan Provincial Cancer Hospital, Henan Cancer Hospital, Zhengzhou University, Tianjin Medical university cancer institute & Hospital,
Abstract
Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6.Org: Lehigh Valley Health Network, University of Oklahoma, Stephenson Cancer Center, H. Lee Moffitt Cancer Center at Memorial Healthcare System, Stony Brook University Medical Center,
Abstract
CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL.Org: Lymphoma and Myeloma Research Amsterdam, St. James's Hospital, BeiGene International GmbH, Department of Haematological Medicine,
Abstract
Phase 3 trial evaluating the efficacy and safety of odronextamab versus standard-of-care (SOC) therapy in relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL; OLYMPIA-4).Org: School of Public Health & Preventative Medicine, Monash University, Melbourne, Australia, Hospital Universitario Doctor Peset, Valencia, Spain, Hospital Virgen de las Nieves, Granada, Spain, Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, Australia, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea,
Abstract
Multicenter, randomized phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy (CAR-T).Org: Huntsman Cancer Institute/University of Utah, Washington University in St. Louis Department of Genetics, Division of Hematology, Mayo Clinic Florida,
Abstract
A phase 1/2, open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplastic activity of IPH6501, a first-in-class NK cell engager, in patients with relapsed and/or refractory CD20-expressing non-Hodgkin lymphoma.Org: Peninsula Health, Peninsula Private Hospital,
Abstract
Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL).Org: UPMC Hillman Cancer Center, University of Pittsburgh, University of Miami/Sylvester Comprehensive Cancer Center, Fred Hutchinson Cancer Center, University of Washington, Mississauga, ON, Canada,
Abstract
Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: A network meta-analysis (NMA).Org: Beigene Netherlands B.V., The Alfred and Monash University,
Abstract
Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).Org: Universitair Ziekenhuis Gent, Health Research Institute IIS-FJD, Lymphoma Service, Memorial Sloan Kettering Cancer Center,
Abstract
Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).Org: Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Sir Charles Gairdner Hospital and the University of Western Australia, The Christie NHS Foundation Trust, Manchester Cancer Research Centre, and Division of Cancer Sciences, University of Manchester,
Abstract
Real world incidence, prevention, and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax in the inpatient and outpatient settings.Org: St. Luke's Roosevelt,
Abstract
Phase 1/2 of EO2463 immunotherapy as monotherapy and in combination with lenalidomide and/or rituximab in indolent NHL (EONHL1-20/SIDNEY).Org: Universidad de Navarra, Madrid and Pamplona, Spain, Vall d'Hebron University Hospital, Barcelona, Spain, Istituto Nazionale Tumori, Fondazione ‘G. Pascale’, IRCCS, Naples, Italy, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy, Hospital Universitario de Salamanca – Complejo Asistencial Universitario de Salamanca, Salamanca, Spain,
Abstract
Association between treatment (tx) response and PFS and OS in R/R chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL): A 12-month landmark (LM) meta-analysis.Org: a Dassault Systèmes Company,
Abstract
EX103: A newly designed CD20×CD3 molecule in heavily pre-treated patients with B-cell non-Hodgkin lymphoma from a phase I/II trial.Org: GCP ward, Institute of Hematology & Hospital of Blood Diseases, Department of Hematology, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, Department of Adult Lymphoma, Beijing GoBroad Boren Hospital, Beijing, China, Department of Hematology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China,
Abstract
Carfilzomib plus rituximab, ifosfamide, carboplatin and etoposide (C-RICE) led to higher response, OS, and PFS in patients with transplant-eligible relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).Org: University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Roswell Park Comprehensive Cancer Center, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Roswell Park Cancer Institute,
Abstract
A phase 1 study of LY007, a novel anti-CD20 CAR-T cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.Org: Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Jiangsu Province Hospital,
Abstract
Glofitamab combined with poseltinib and lenalidomide for relapsed/refractory diffuse large B cell lymphoma: Interim analysis of GPL study.Org: Wonju Severance Christian Hospital, Chonbuk Natioanl University Medical School and Hospital, Chungnam National University Sejong Hospital,
Abstract
Immunologic effects of B cell depletion on T cells in high-risk prostate cancer.Org: University of California, San Diego Center for Advanced Laboratory Medicine, MaineHealth Cancer Care,
Abstract
Results from the follicular lymphoma (FL) outcomes in patients (pts) with relapsed/refractory (R/R) disease treated with systemic therapy in a real-world assessment (FLORA) study.Org: Regeneron Pharmaceuticals, Inc., IQVIA, Amsterdam, Netherlands,
Abstract
Frontline treatment with zanubrutinib plus rituximab (ZR) followed by short course R-DHAOx in patients with mantle cell lymphoma (MCL): Results of the phase II CHESS clinical trial.Org: Department of Hematology, Huizhou Municipal Central Hospital, Department of Medical Oncology, The Second Hospital of Dalian Medical University, Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University,
Abstract
HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory diffuse large B-cell lymphoma: A single agent phase IIa trial.Org: Department of Hematology,The First Affiliated Hospital of Chongqing Medical University, Department of Hematology and Oncology, Chongqing University Cancer Hospital, Department of Hematology Oncology, YunNan Provincial Cancer Hospital, Department of Lymphoma Medicine, Hubei Cancer Hospital, Department of Lymphoma and Hematology, Hunan Cancer Hospital,
Abstract
Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: Updated results from EPCORE NHL-2.Org: Department of Internal Medicine – Hematology, Assistance Publique – Hôpitaux de Marseille (AP-HM), University Hospitals Plymouth NHS Trust, Clinical Hematology Department, On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC,
Abstract
Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).Org: Colorado Blood Cancer Institute and Sarah Cannon Research Institute, Ascentage Pharma Pty Ltd.,
Abstract
Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2).Org: The Cancer and Hematology Centers, Grand Rapids, MI, Community Cancer Trials of Utah, Ogden, UT, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, Department of Hematology, Sakarya University, Sakarya, Turkey, Gazi Universitesi Tip Fakültesi, Ankara, Turkey,
Abstract
Impact of bridging therapy (BT) on lisocabtagene maraleucel (liso-cel) treatment in patients (pt) with R/R follicular lymphoma (FL).Org: Universität zu Köln, Karolinska Institutet and University Hospital, Montpellier University Hospital Center, Groupe de Recherche sur les formes Injectables et les Technologies Associées,
Abstract
LOTIS-5: An ongoing, phase 3, randomized study of loncastuximab tesirine with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL.Org: Centrum Medyczne Pratia Poznań, Department of Oncology and Hematology, Humanitas University and IRCCS Humanitas Research Hospital, ADC Therapeutics SA, ADC Therapeutics Ltd., ADC Therapeutics America, Inc.,
Abstract
BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).Org: Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele,
Abstract
Clinical activity and safety of naptumomab estafenatox (NAP) and docetaxel in patients (pts) with checkpoint inhibitor (CPI) –pretreated advanced/metastatic non-small cell lung cancer (NSCLC): Preliminary results of a P2 trial.Org: Texas Oncology Odessa, NeoTx Ltd,
Abstract
Preliminary results from a phase I study of IMM0306 in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.Org: Affiliated Cancer Hosiptal of Zhengzhou University, ImmuneOnco Biopharmaceuticals (Shanghai) Inc.,
Abstract
Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): Results from a phase I/II study.Org: Rigshospitalet and University of Copenhagen,
Abstract
Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator’s choice in previously untreated follicular lymphoma (OLYMPIA-1).Org: Hematology Oncology of Indiana/American Oncology Network, Azienda Unità Sanitaria Locale-IRCCS, Gazi Universitesi Tip Fakültesi, ProHealth Care,
Abstract
First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A+O) +/- radiotherapy (RT): Results from the FLUORO study.Org: Grampians Health, Austin Health and University of Melbourne, Olivia Newton-John Cancer Research Institute and La Trobe University, Murdoch Children's Research Institute,
Abstract
Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).Org: Turin, Italy, Varese, Italy, Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, Waukesha, WI,
Abstract
EPCORE FL-2: Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy or R2 in previously untreated follicular lymphoma.Org: Manchester Cancer Research Centre, Sir Peter MacCallum Cancer Centre Melbourne, University of Modena and Reggio Emilia,
Abstract
Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3).Org: Division of Blood Disorders, Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, Namık Kemal Üniversitesi, Nantes University Hospital, Centre Hospitalier Universitaire (CHU) de Poitiers,
Abstract
Development of HLB3-002 (recombinant human PH20 stand-alone) and its applicability as an anticancer diffusion agent.Org: Huonslab,
Abstract
Efficacy and safety of mosunetuzumab-based regimens as first-line therapy in non-Hodgkin lymphomas: A systematic review of clinical trials.Org: New York Medical College at St.Michael's, New York Medical College at St. Michael’s Medical Center,
Abstract
Genomic profiling in a subgroup analysis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and extranodal (EN) sites of involvement in the phase 3 Pola-R-CHP versus R-CHOP (POLARIX) study.Org: Centre Henri-Becquerel and University of Rouen, University Hospital Münster, M.D. Anderson Cancer Center, Charles University General Hospital, University of Montpellier,
Abstract
PMB-CT01 (BAFFR-CAR T cell) therapy to examine preliminary safety and clinical responses in patients with B-cell malignancies who are ineligible for or failed CD19-directed therapy, including CD19-negative disease.Org: City of Hope National Medical Center, PeproMene Bio,
Abstract
Preliminary results of a first-in-human study on ESG206, a novel anti-BAFF-R monoclonal antibody, in relapsed or refractory B-cell malignancies.Org: Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China, Department of Lymphatic Oncology, Beijing Cancer Hospital, Beijing, China, Department of Hematology, Beijing Hospital, Beijing, China, Shanghai Escugen Biotechnology Co., Ltd., Shanghai, China, Shanghai Escugen Biotechnology Co., Ltd., Beijing, China,
Abstract
A study of a new mechanism: Intracellular retention allo-CART safety and efficacy for extranodal bulky B-NHL.Org: Fundamenta Therapeutics Co., Ltd., The First Affiliated Hospital of University of Science and Technology of China,
Abstract
Therapeutic utilization in chronic lymphocytic leukemia: A cross-sectional analysis of the Lymphoma Coalition’s 2022 Global Patient Survey.Org: Lymphoma Coalition,
Abstract
Outcomes in patients (pts) with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) treated with systemic therapy from real world experience (ORCHID) study.Org: Hematology Institute, Clinical Department of Hematology,
Abstract
Real-world cost of disease progression (PD) after frontline (1L) R-CHOP in diffuse large B-cell lymphoma (DLBCL): An analysis of a large US claims database.Org: Rocky Mountain Cancer Centers, The US Oncology Network, Aurora, CO, Genentech, South San Francisco, CA,
Abstract
Effect of rituximab on remissions without minimal residual disease and immunogenicity in patients with relapsed/refractory hairy cell leukemia receiving moxetumomab pasudotox.Org: Laboratory of Molecular Biology, NCI, NIH, Bethesda, MD, Laboratory of Pathology, NCI, NIH, Bethesda, MD, Office of Research Nursing, NCI, NIH, Bethesda, MD, Hematology Service, DLM, NIH, Bethesda, MD,
Abstract
Quantitative systems pharmacology (QSP) model to predict combination activity of CD19-targeted antibody drug conjugate (loncastuximab tesirine) co-dosed with a CD20/CD3 T-cell bispecific (epcoritamab) in patients with diffuse large B-cell lymphoma (DLBCL).Org: Murray Hll, Metrum Research Group, Tariffville,
Abstract
EPCORE NHL‑1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL.Org: Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, Manchester Cancer Research Centre, The Christie NHS Foundation Trust, University of Manchester, Manchester, United Kingdom, Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland,
Abstract
Effect of 1-L-MT on immunotherapy of diffuse large B-cell lymphoma via downregulation of PD-L1.Org: Shandong Provincial Qianfoshan Hospital,
Abstract
Real-world comparison of time to next treatment for patients with high-risk CLL/SLL in first line of treatment.Org: University of Pittsburgh Medical Center (UPMC), Integra Connect PrecisionQ,
Abstract
Health-related quality of life (HRQoL), functioning, and symptoms with odronextamab monotherapy in patients (pts) with relapsed or refractory follicular lymphoma (R/R FL) by POD24 status in the ELM-2 study.Org: IQVIA, Amsterdam, Netherlands,
Abstract
Phase I safety and preliminary efficacy of IMM0306 in combination with lenalidomide in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.Org: Lymphatic Comprehensive Internal Medicine Ward, Henan Cancer Hospital, Henan Cancer Hospital, Department of Lymphoma, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Shanghai, China,
Abstract
Prevalence of adverse events following bispecific antibody therapy in non-Hodgkin lymphoma: A meta-analysis.Org: Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Mayo Clinic, Mayo Clinic Arizona, Phoenix, AZ, Mayo Clinic Scottsdale,
Abstract
Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome.Org: Niguarda Cancer Center, Laboratory of Experimental Hematology, Clinic of Hematology, Ente Ospedaliero Cantonale, Universita’ della Svizzera italiana,
Abstract
Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).Org: Alliance Statistics and Data Management Center, Alliance Protocol Operations Office, Illinois CancerCare, Mayo Clinic, Trinity Health Saint Joseph Mercy Hospital,
Abstract
Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed/refractory T-ALL.Org: Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Texas Children's Hospital,
Abstract
Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial.Org: Oncology Institute of Southern Switzerland, Institute of Oncology Research, Università della Svizzera italiana, Bellinzona, Switzerland, University of Southampton,
Abstract
Biosimilar uptake and cost savings analysis before and after implementation of a pharmacist-driven substitution program within a National Community Oncology Network: One-year follow-up.Org: American Oncology Network Pharmacy, Fort Myers, FL,
Abstract
Real-world outcomes with novel therapies in R/R DLBCL.Org: Dana-Farber Cancer Institute, Genmab US, Inc., AbbVie Inc., North Chicago, IL,
Abstract
Antineoplastic and immunomodulating agent effects on immunization outcomes.Org: Scripps Clinic/Green Hospital, Whittier Diabetes Institute, Scripps Health, Scripps Research Translational Institute, Center for Organ & Cell Transplant,
Abstract
Preliminary results from a phase I/II study of IMM0306, a CD47 and CD20 bispecific monoclonal antibody-trap, in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.Org: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, The First Affiliated Hospital of Zhengzhou University,
Abstract
SAVE (Safe Accelerated Venetoclax Escalation): Initial results of a prospective, phase Ib study of venetoclax with an accelerated dose ramp-up in patients with CLL.Org: Dana-Farber Cancer Institute, Department of Data Sciences, DFCI/PCC Fellowship Program - Attendings,
Abstract
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.Org: Levine Cancer Institute, Wilmot Cancer Institute, BC Cancer Centre for Lymphoid Cancer, Willamette Valley Cancer Institute and Research Center, US Oncology Research,
Abstract
System-wide approach on biosimilars adoption in oncology: Strategic plan on switching and cost savings.Org: Cedars-Sinai Medical Center, Cedars-Sinai Medical Center Medical, Cedars-Sinai Cancer, Cedars-Sinai Cancer Beverly Hills, Cedars-Sinai Cancer Tarzana,
Abstract
Evaluation of outcomes between rituximab-abbs and reference product rituximab in adult patients with newly diagnosed diffuse large B-cell lymphoma in a non-inferiority study.Org: Kaiser Permanente Oakland Medical Center, Kaiser Permanante, Kaiser Permanente Davis, Kaiser Permanante Irvine, Kaiser Permanente Pasadena,
Abstract
BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations.Org: Istanbul Medipol University Medical Faculty, International School of Medicine, Merck & Co., Inc., Rahway, NJ, Maria Sklodowska-Curie National Institute of Oncology,
Abstract
Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.Org: Lymphoma Service, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Vejle Hospital, Universitair Ziekenhuis Gent, Ronald Reagan University of California Los Angeles Medical Center,
Abstract
Osmotic blood-brain barrier disruption with mannitol followed by methotrexate, rituximab, and carboplatin in treating patients with newly diagnosed primary central nervous system lymphoma.Org: Providence Brain and Spine Institute, Oregon Health & Science University, Oregon Health and Science University,
Abstract
Factors associated with severe immune checkpoint inhibitor-induced pneumonitis.Org: The Ohio State University - James Cancer Hospital, The Ohio State University - Biostatistics Department, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH,
Abstract
A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL).Org: Brown University - Lifespan Cancer Institute, Yale University, Rhode Island Hospital, Lifespan Oncology Clinical Research, Brown University Oncology Research Group,
Abstract
MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.Org: MD Anderson Cancer Center, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, University of British Columbia, Institut Curie, Saint Cloud, France, University of Bologna,
Abstract
SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.Org: MD Anderson Cancer Center, Brown University - Lifespan Cancer Institute, Hospital de Clinicas de Porto Alegre, Samsung Medical Center, Pusan National University Hospital,
Abstract
Phase II trial of split-dose R-CHOP for older patients with diffuse large B-cell lymphoma (DLBCL).Org: Medical College of Wisconsin, Froedtert & Medical College of Wisconsin, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, University of Wisconsin Madison School of Medicine and Public Health, Division of Hematology & Oncology,
Abstract
Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (LOTIS-7).Org: Blood and Marrow Transplant Group of Georgia, Virginia Cancer Specialists, ADC Therapeutics America, Inc., Institute of Hematology “Seràgnoli”, Oxford University Hospitals, NHS Trust,
Abstract
Effectiveness and safety outcomes in patients with EBV+ PTLD treated with allogeneic EBV-specific T-cell immunotherapy (tabelecleucel) under an expanded access program (EAP) in Europe.Org: Atara Biotherapeutics, Inc., Atara Biotherapeutics Switzerland GmbH,
Abstract
AB-101, an allogeneic, non–genetically modified, natural killer (NK) cell therapy, evaluated as monotherapy or in combination with rituximab in R/R non-Hodgkin lymphoma.Org: Fox Chase Cancer Center, O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham School of Medicine, Norton Cancer Institute, Texas Oncology PA, OHSU - Oregon Health and Science University,
Abstract
Safety and efficacy of ABR in pts with TN or R/R MCL: Ph Ib trial.Org: AstraZeneca, Cambridge, United Kingdom, AstraZeneca, South San Francisco, CA,
Abstract
Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Washington and Fred Hutchinson Cancer Research Centre, Seagen, Inc.,
Abstract
Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial.Org: University of Michigan Comprehensive Cancer Center, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, MSC National Research Institute of Oncology, Kraków, Poland, Sir Charles Gairdner Hospital,
Abstract
Preliminary data of a phase 1b/2 study of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).Org: Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group, Jiangsu Ascentage Pharma Pty Ltd.,
Abstract
Efficacy of COVID vaccinations in patients with chronic lymphocytic leukemia.Org: The Ohio State University - James Cancer Hospital, UT Southwestern Medical Center, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Ohio State University Comprehensive Canvcer Hospital,
Abstract
waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).Org: Hadassah Medical Center, Ankara University School of Medicine, Maria Sklodowska-Curie National Research Institute of Oncology, Institut Català d'Oncologia Hospitalet, Samsung Medical Center,
Abstract
BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma.Org: US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Department of Hematology and Cancer Prevention, Medical University of Silesia, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Memorial Sloan Kettering Cancer Center,
Abstract
Patient perspectives on CLL treatment side effects: A sub-analysis of the VOICE survey.Org: Alfred Health, H. Lee Moffitt Cancer Center and Research Institute, Antalya Research and Training Hospital, Fundaleu, University Hospital Hradec Králové,
Abstract
A study of frontline therapy in adults >80 years with chronic lymphocytic leukemia (CLL).Org: Mayo Clinic, Division of Clinical Trials and Biostatistics, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Department of Laboratory and Oncology, Mayo Clinic, Rochester, MN, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN,
Abstract
Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma.Org: IRCCS Humanitas Research Hospital, Rozzano, Italy, Humanitas University, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki University Hospital Comprehensive Cancer Center, Semmelweis University,
Abstract
ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Dana-Farber Cancer Institute, MD Anderson Cancer Center, University of Lille,
Abstract
BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.Org: Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, Faculty Hospital Hradec Kralove,
Abstract
Immunomodulatory AVM0703 enhances R-CHOP anti-lymphoma effect with reduced toxicity: Immune-resistant, aggressive A20 lymphoma model.Org: AVM Biotechnology, Inc., AVM Biotechnology,
Abstract
Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study.Org: Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy, Hôpital Claude Huriez and CHU de Lille, Lille, France, Rigshospitalet, Copenhagen, Denmark, Centre Hospitalier Lyon-Sud, Lyon, France, CHU de Montpellier, Montpellier, France, Allegheny Health Network, Pittsburgh, PA, Ospedale Santa Maria delle Croci, Ravenna, Italy, Department of Hematology, Hospital Universitario 12 de Octubre, Complutense University, CNIO, CIBERONC, Madrid, Spain, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, Department of Hematology, Hospital del Mar, Passeig Maritim, 08003 Barcelona, Spain, Tisch Cancer Institute, New York, NY, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland, F. Hoffmann-La Roche Ltd, Basel, Switzerland, Roche Products Ltd, Welwyn Garden City, United Kingdom, F. Hoffmann-La Roche Ltd, Mississauga, ON, Canada, Peter MacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne, Melbourne, Vic, VIC, Australia,
Abstract
Evaluating the effectiveness and tolerability of chemotherapy in hairy cell leukemia: A comprehensive systematic review and meta-analysis.Org: Rawalpindi Medical University, King Edward Medical University, King Edward Medical University Pakistan, North Shore University Hospital, Mercy Catholic Medical Center, Lansdowne, PA,
Abstract
COVID-19 infection in patients on anti-CD20 monoclonal antibodies: Changes in clinical outcomes and management over time.Org: University of South Dakota Sanford School of Medicine (Sioux Falls, SD), Sioux Falls, SD, Sanford USD Medical Center, University of South Dakota Sanford School of Medicine, Sanford Health,
Abstract
Feasibility of CAR-T in very old patients with relapsed/refractory diffuse large B-cell lymphoma.Org: H. Lee Moffitt Cancer Center and Research Institute,
Abstract
Final analysis of the phase IB part of the LOC-R01 trial, a non-comparative randomized phase IB/II study of escalating doses of lenalidomide and ibrutinib in association with R-MPV for patients with a newly diagnosed primary central nervous system lymphoma (PCNSL).Org: Institut Curie, Saint Cloud, France, Institut Curie, Biostatistics Unit, Centre Henri-Becquerel and University of Rouen, Bergonié Institute, Neurology, Assistance Publique – Hôpitaux de Paris (APHP), Sorbonne Université, IHU, ICM, Groupe Hospitalier Pitié-Salpêtrière,
Abstract
Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.Org: Institute of Hematology “Seràgnoli”, University of Bologna, Bologna, Italy, Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital, Brno, Czech Republic, Institut Bergonié, Bordeaux, France, Institut Catala d'Oncologia (ICO) Hospital Duran I Reynals, Hospital, Barcelona, Spain, Peking University Cancer Hospital & Institute, Beijing, China,
Abstract
Outcomes of stereotactic radiosurgery in central nervous system lymphoma: A single institution experience.Org: University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Roswell Park Comprehensive Cancer Center,
Abstract
Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study.Org: The Peter MacCallum Cancer Centre, Royal Melbourne Hospital, The University of Melbourne, Department of Internal Medicine III, University Hospital Ulm, Klinik für Innere Medizin I, Hämatologie, Onkologie und Stammzelltransplantation Centrum für Chronische Immundefizienz (CCI),
Abstract
Real-world data on incidence of acute adverse reactions (AARs) reported in clinical practice.Org: Medical Day Hospital Unit Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Medical Day Hospital Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Pharmacy Unit Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori-University of Milan,
Abstract
ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.Org: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, Dana-Farber Cancer Institute, Boston, MA, USA, Moffitt Cancer Center and Research Institute, Tampa, FL, Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain, University of Lille, Centre Hospitalier Universitaire, Lille, France,
Abstract
Early detection of CRS after CAR-T therapy using wearable monitoring devices: Preliminary results in relapsed/refractory multiple myeloma (RRMM).Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Current Health, Dorset County Hospital, NHS Foundation Trust, Tisch Cancer Institute, Mount Sinai School of Medicine,
Abstract
Association of COVID-19 pandemic with indolent lymphoma care delivery and outcomes in Ontario, Canada: A population-based analysis.Org: Princess Margaret Cancer Centre, University Health Network, Department of Medicine, Icahn School of Medicine at Mount Sinai, University of Toronto, Institute for Clinical Evaluative Sciences,
Abstract
Mini-hyper-CVD plus inotuzumab ozogamicin (InO), with or without blinatumomab (Blina), in older patients with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL): Updates from a phase II trial.Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Diffuse large B-cell lymphoma in HHV8+ multicentric Castleman disease: A national analysis of demographic features.Org: Creighton University School of Medicine-Phoenix, Creighton University School of Medicine Phoenix Regional Campus, Creighton School of Medicine - Phoenix Regional Campus, Creighton Hematology Oncology, Omaha, NE, Creighton University School of Medicine (Phoenix Regional Campus), Phoenix, AZ,
Abstract
Association of SARS-CoV-2 vaccinations and personal protective measures with seroconversion and risk of infection in a large real-world cohort of patients with cancer.Org: DKFZ-Hector Cancer Institute and Department of Personalized Oncology, University Medical Center Mannheim, Division of Personalized Medical Oncology, German Cancer Research Center (DKFZ), German Center for Lung Research (DZL),
Abstract
Practice efficiency of treatment with epcoritamab versus glofitamab in relapsed/refractory diffuse large B-cell lymphoma.Org: Xcenda, LLC, Carrollton, TX, Alkemi LLC, Manchester Center, VT, AbbVie Inc., North Chicago, IL,
Abstract
Outcome differences by sex in oncology clinical trials.Org: Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, Medical College of Wisconsin, WIN Consortium,
Abstract
Mini-hyper-CVD with venetoclax (Ven) for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): A phase II study.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Five-year subgroup analysis of tafasitamab + lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma.Org: Vall d’Hebron Institute of Oncology (VHIO), Ludwig-Maximilians-University Hospital, University of Eastern Piedmont, Institut Català D'Oncologia, IDIBELL,
Abstract
Phase II trial of mini-hyper-CVD-inotuzumab (InO) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, Chao Family Comprehensive Cancer Center, University of California, Irvine, CA,
Abstract
Low-intensity chemotherapy (mini-HCVD) and ponatinib followed by blinatumomab (blina) and ponatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): A phase II study.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,